These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20689121)

  • 21. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Liraglutide: new results in the treatment of type 2 diabetes mellitus].
    Mateos JL; Wajchenberg BL
    Drugs Today (Barc); 2012 Jul; 48 Suppl B():1-17. PubMed ID: 23082308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.
    Gallwitz B; Vaag A; Falahati A; Madsbad S
    Int J Clin Pract; 2010 Jan; 64(2):267-76. PubMed ID: 19925617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liraglutide: a review of its use in type 2 diabetes mellitus.
    Croom KF; McCormack PL
    Drugs; 2009 Oct; 69(14):1985-2004. PubMed ID: 19747013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
    Reboldi G
    G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
    Courrèges JP; Vilsbøll T; Zdravkovic M; Le-Thi T; Krarup T; Schmitz O; Verhoeven R; Bugáñová I; Madsbad S
    Diabet Med; 2008 Sep; 25(9):1129-31. PubMed ID: 19183322
    [No Abstract]   [Full Text] [Related]  

  • 28. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2014 Dec; 74(18):2161-74. PubMed ID: 25367717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
    Davies MJ; Kela R; Khunti K
    Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B
    Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
    Jahn E; Sausele T
    Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus.
    Marino AB; Cole SW; Nuzum DS
    Am J Health Syst Pharm; 2014 Feb; 71(3):223-6. PubMed ID: 24429016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide Effect and Action in Diabetes (LEAD™) trial.
    Madsbad S
    Expert Rev Endocrinol Metab; 2009 Mar; 4(2):119-129. PubMed ID: 30780853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is liraglutide a useful addition to diabetes therapy?
    Mikhail NE
    Endocr Pract; 2010; 16(6):1028-37. PubMed ID: 20439238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
    Zenari L
    Acta Biomed; 2011 Dec; 82(3):251-3. PubMed ID: 22783722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pharmacokinetic Properties of Glucagon-like Peptide-1 Receptor Agonists and Their Mode and Mechanism of Action in Patients with Type 2 Diabetes.
    Anderson J
    J Fam Pract; 2018 Jun; 67(6 suppl):S8-S13. PubMed ID: 29912996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.